×
About 12,180 results

Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China
https://www.onclive.com/view/pembrolizumab-maintains-survival-benefits-in-4-year-follow-up-of-keynote-042-in-nsclc-in-china

Apr 9th, 2022 - First-line pembrolizumab (Keytruda) monotherapy continued to elicit an overall survival (OS) benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer (NSCLC) without sensitizing EGFR or ALKmutations, according to results of a 4-year follow-up from the phase 3 KEYNOTE-04...

Unexpected but Potentially Actionable Cancer Clinical Trial Results: What Happens Next?
https://www.onclive.com/view/unexpected-but-potentially-actionable-cancer-clinical-trial-results-what-happens-next-

Apr 4th, 2022 - There should be little or no debate with the statement that clinical trials serve as the primary source of data employed to favorably affect outcomes for patients who receive a diagnosis of cancer. However, much can be said regarding well-described deficiencies in the existing trial process and, unfortunately, the often ineffective efforts to improve this critical component of cancer care and r...

ASCO/CAP Issue New Guidelines for IHC Hormone Testing in Breast Cancer
https://www.onclive.com/view/ihc_hormone_testing

Mar 15th, 2022 - The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) jointly released guidelines designed to improve the accuracy and usefulness of immunohistochemical (IHC) testing for estrogen receptor (ER) and progesterone receptor (PgR) status in breast cancer tumors after convening a panel of international experts to study the issue. After reviewing 337 studies i...

The Year in Breast Cancer: The Top Five Under-appreciated Developments of 2008
https://www.onclive.com/view/year_in_breast_cancer

Mar 15th, 2022 - 2008 was a busy year in the field of breast cancer medicine, with thousands of abstracts presented at the ASCO, ASCO breast, and ESMO meetings and the San Antonio Breast Cancer Symposium in December, in addition to the many papers published over the course of the year (a PubMed search reveals that 5,252 papers published in the last year contained the words breast cancer in the title). Some of t...

Roche
https://www.onclive.com/view/onc_roche

Mar 15th, 2022 - "New technologies and areas of research are the basis for today’s revolution in medicine, according to the Roche Breakthrough Technologies research area website (www. roche.com/home/science/sci_res/sci_res_tech.htm). In combination with information technology, automation and new chemical techniques, biosciences have the tools to develop new and better drugs.” Below, we explore what Roche is doi...

5 CINV Web Resources for Patients
https://www.onclive.com/view/cinv_web_resources

Mar 15th, 2022 - Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and most feared side effects of chemotherapy. When CINV occurs, it may decrease treatment compliance and result in nutritional deficiencies or dehydration, reduced performance status, and decreased quality of life. Preventing and controlling CINV is imperative for optimizing the care of patients receiving chemotherapy. Al...

Medical Marijuana Is a Trojan Horse That Pain Physicians Should Refuse to Accept
https://www.onclive.com/view/medical-marijuana-is-a-trojan-horse-that-pain-physicians-should-refuse-to-accept

Mar 15th, 2022 - Forty-six percent of Americans want marijuana to be legalized. Seventy percent of Americans support the legalization of medical marijuana. The large gap between these 2 figures provides just enough wiggle room for politicians lacking in backbone to squeeze through and try to make everyone happy. The problem is that they are using physicians as a Trojan horse to do it--and pain physicians should...

5 Questions... with Charles Morris, MD, VP of Worldwide Clinical Research, for Cephalon Oncology
https://www.onclive.com/view/ong_5qs_with_charles_morris

Mar 15th, 2022 - 1 Why are self-survival and self-renewing pathways such promising areas of discovery at this time for Cephalon? If we can understand the methods and the pathways by which cells are able to either prolong their survival or sustain their own proliferation as tumors grow, then, by identifying targets along those pathways, we have the opportunity to develop drugs to interfere with and block those ...

Extraordinary Care Is the Mission of the John Theurer Cancer Center
https://www.onclive.com/view/john_theurer_cancer_center

Mar 15th, 2022 - This Month's Featured Institution: John Theurer Cancer Center The John Theurer Cancer Center at Hackensack University Medical Center in New Jersey has been a leader in the diagnosis, treatment, management, and prevention of cancer for more than 30 years. Last year alone it prepared close to 300,000 inpatient and outpatient chemotherapy sessions. And the Center enrolls far more patients in cli...

Folding@home: How Distributed Computing Is Unraveling the Mysteries of Protein Folding
https://www.onclive.com/view/protein_folding_playstation_3

Mar 15th, 2022 - In October 2000, a team of researchers at Stanford University led by Vijay Pande, PhD, debuted a distributed computing project designed to simulate the protein folding process. These simulations were developed to complement and aid formal experiments. Dubbed Folding@home (FAH), the project uses autonomous individual computer processors around the world to run complex computing algorithms that w...

Last Writes: It's Nearly Spring... Time for Skiing!
https://www.onclive.com/view/ong_lastwrites_spring

Mar 15th, 2022 - Here in the Northeast, March is a month of anticipated change. After the short, cold, and dark days of February, March means still having some daylight left as we leave the office, the occasional spring tease of a mild day, and often the fi rst signs of spring growth on the trees. And yet, every March, I find myself thinking about skiing. Being an eastern skier, I’ve been burned too many times...

NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management
https://www.onclive.com/view/now_initiative

Mar 15th, 2022 - Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collab...

Grow Up!
https://www.onclive.com/view/onc-growup

Mar 15th, 2022 - Since I can remember, I've been playing video games. I was a console junky in my early years, starting with the Atari 2600, moving to the ColecoVision and their ADAM computer, trading up to a Nintendo Entertainment System, then getting a Sega Genesis, the Sega 32X and CD, a Sony Playstation, Playstation 2, and finally an Xbox. Now, I’m a grown man playing an Xbox 360 with a Live account. I know...

Electronic Ordering System Improves Chemotherapy Care
https://www.onclive.com/view/electronic-ordering-system-improves-chemotherapy-care

Mar 15th, 2022 - Andrew D. Zelenetz, MD Chief, Lymphoma Service Department of Medicine Memorial Sloan-Kettering Cancer Center Associate Professor of Medcine Weill Cornell Medical College New York, NY Oncologists have spent years determining the proper dosing amounts of chemotherapies for patients with different types and stages of cancer, yet all of that knowledge can be derailed in an i...

Nine Must-Have Cancer Tools
https://www.onclive.com/view/ong_nine_cancer_tools

Mar 15th, 2022 - Modern oncologists have a vast array of tools and information at their disposal that can help them deliver better care to their patients, run their practices more efficiently, and stay up to date with the latest research. In fact, there are so many tools available that it can be next to impossible to sort through them all and determine which ones are truly the most useful. We consulted several ...

The Right System for the Right Price: To Avoid EHR Sticker Shock, You Have to See the Big Picture
https://www.onclive.com/view/avoid_ehr_sticker_shock

Mar 15th, 2022 - The decision to move from a paper-based oncology practice to one based on an EHR system can be onerous and intimidating, in part because there are literally hundreds of vendors with products on the market, each with different cost structures, feature sets, and ability to connect and share data with other systems. When you also consider the inevitable post-implementation disruption to workflow a...

Healthcare IT Still Seeks a Security Blanket
https://www.onclive.com/view/healthcare_1109

Mar 15th, 2022 - August has traditionally been a sleepy month for government regulatory agencies, but this year, Washington’s usual summer torpor was interrupted by a rush of new initiatives, as more than three-quarters of a trillion dollars from the American Recovery and Reinvestment Act (www.recovery.gov) surged into a mind- boggling range of projects. One of these efforts, the Health Information Technology f...

Sirolimus After Liver Transplant Improves Survival
https://www.onclive.com/view/sirolimus

Mar 15th, 2022 - In the April issue, researchers from the University of Alberta in Edmonton, Canada, reported that administering sirolimus (Rapamune) after liver transplantation in patients with nonresectable hepatocellular carcinoma (HCC) significantly increased survival rates. An anti-CD25 antibody induction regimen improved survival in liver transplant patients regardless of whether they had HCC. Investigat...

From Pronouncement to Partnership: Understanding New Modes of Communication in a Changing Healthcare System
https://www.onclive.com/view/new_modes_of_communication

Mar 15th, 2022 - The dramatic change in healthcare delivery from private practitioner-based to managed care created a vacuum of responsibility for self care that the patient has needed to fill. In response to this, the lay cancer community has created a sophisticated model for offering and disseminating updated information for the Web-savvy information seeker. Its success has accelerated a fundamental change in...

Type 1 Gaucher Disease Growing Awareness of a Rare Disorder
https://www.onclive.com/view/type_one_gaucher_disease

Mar 15th, 2022 - In March, we published data from the Lysosomal Disease Network WORLD Symposium on new treatment options being studied for type 1 Gaucher disease. Gaucher disease is a lysosomal storage disorder (LSD) that occurs in approximately 1 of every 20,000 births. This inherited genetic condition is rare; fewer than 10,000 people in the world have Gaucher disease. People of Ashkenazi Jewish descent have ...